Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Epirubicin and CMF in Aggressive Breast Cancer
NCT01031030Phase 3Unknown
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Nov 1997
- Primary completion
- Dec 2010
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 3, randomised, open-label trial of epirubicin in breast cancer (3 arms), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Overall Survival. Status: unknown.
02
Drugs
epirubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01031030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01031030.